Table 3.
The change in clinical examination after sodium-glucose cotransporter 2 inhibitors treatment for six months.
| Characteristics | Baseline (n = 62) |
Follow-up 1a (n = 62) |
Follow-up 2b (n = 62) |
p value |
|---|---|---|---|---|
| Initial proteinuria, g/24 h median, IQR | 1.39 (0.99 to 2.35) | 1.08 (0.71–1.78) | 1.09 (0.60–1.83) | <0.001 |
| Albumin, g/L, mean ± SD | 40.2 ± 4.4 | 41.0 ± 4.0 | 41.0 ± 4.1 | 0.017 |
| eGFR, ml/min/1.73m2 mean ± SD | 58 ± 23 | 56 ± 23 | 55 ± 23 | 0.012 |
| SBP, mmHg, mean ± SD | 125 ± 12 | 126 ± 12 | 123 ± 10 | 0.252 |
| DBP, mmHg, mean ± SD | 80 ± 10 | 80 ± 9 | 77 ± 9 | 0.071 |
| Urine sodium excretion median, IQR | 160 (120 to 197) | 154 (119 to 222) | 158 (127 to 212) | 0.042 |
| Hematuria, RBC/μL | 13.1 (4.0 to 62.2) | 10.0 (3.8 to 34.7) | 9.5 (1.5 to 34.6) | 0.01 |
a
Follow-up at 3 months after SGLT2i treatment.
b
Follow-up at 6 months after SGLT2i treatment; SD, standard deviation; IQR, interquartile range; eGFR, estimated glomerular filtration rate; SBP, systolic blood pressure; DBP, diastolic blood pressure; RBC, red blood cell; HPF, high-power field.